Thiamine transporter gene expression and exogenous thiamine modulate the expression of genes involved in drug and prostaglandin metabolism in breast cancer cells

Molecular Cancer Research

Volumn 2, Issue 8, 2004, Pages 477-487

  Liu, Shuqian ^a   Stromberg, Arnold ^b   Tai, Hsin Hsiung ^c   Moscow, Jeffrey A ^a,d  

^a UNIVERSITY OF KENTUCKY   (United States)

^b UNIVERSITY OF KENTUCKY   (United States)

^c University of Kentucky   (United States)

^d NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

15 HYDROXYPROSTAGLANDIN DEHYDROGENASE; CARRIER PROTEIN; CYTOCHROME P450 4B1; PROSTAGLANDIN; RHO GUANINE NUCLEOTIDE BINDING PROTEIN; THIAMINE TRANSPORTER; UNCLASSIFIED DRUG;

ARTICLE; BREAST CANCER; CANCER CELL CULTURE; DNA MICROARRAY; DRUG METABOLISM; GENE; GENE EXPRESSION REGULATION; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROSTAGLANDIN METABOLISM; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; THTR2 GENE;

BLOTTING, WESTERN; BREAST NEOPLASMS; CELL LINE, TUMOR; DOWN-REGULATION; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; KINETICS; LUNG NEOPLASMS; MEMBRANE TRANSPORT PROTEINS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PHARMACEUTICAL PREPARATIONS; PROSTAGLANDINS; RNA INTERFERENCE; RNA, MESSENGER; THIAMINE;

LOTUS;

EID: 4344702050     PISSN: 15417786     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Basu TK, Dickerson JW. The thiamin status of early breast cancer patients with particular reference to those with breast and bronchial carcinomas. Oncology 1976;33:250-2.
2. Altucci L, Gronemeyer H. The promise of retinoids to fight against cancer. Nat Rev Cancer 2001;1:181-93.
3. Willett WC. Diet and cancer: one view at the start of the millennium. Cancer Epidemiol Biomarkers & Prev 2001;10:3-8.
4. Wiemels JL, Smith RN, Taylor GM, Eden OB, Alexander FE, Greaves MF. Methylenetetrahydrofolate reductase (MTHFR) polymorphisms and risk of molecularly defined subtypes of childhood acute leukemia. Proc Natl Acad Sci U S A 2001;98:4004-9.
5. Liu S, Huang H, Lu X, et al. Down-regulation of thiamine transporter THTR2 gene expression in breast cancer and its association with resistance to apoptosis. Mol Cancer Res 2003;1:665-73.
6. Willey JC, Coy E, Brolly C, et al. Xenobiotic metabolism enzyme gene expression in human bronchial epithelial and alveolar macrophage cells. Am J Respir Cell Mol Biol 1996;14:262-71.
7. Czerwinski M, McLemore TL, Gelboin HV, Gonzalez FJ. Quantification of CYP2B7, CYP4B1, and CYPOR messenger RNAs in normal human lung and lung tumors. Cancer Res 1994;54:1085-91.
8. Heighway J, Knapp T, Boyce L, et al. Expression profiling of primary nonsmall cell lung cancer for target identification. Oncogene 2002;21:7749-63.
9. Anggard E. The biological activity of three metabolites of prostaglandin E1. Acta Physiol Scand 1966;66:509-10.
10. Badawi AF, Badr MZ. Chemoprevention of breast cancer by targeting cyclooxygenase-2 and peroxisome proliferator-activated receptor-γ [review]. Int J Oncol 2002;20:1109-22.
11. Singh B, Lucci A. Role of cyclooxygenase-2 in breast cancer. J Surg Res 2002;108:173-9.
12. Dubinett SM, Sharma S, Huang M, Dohadwala M, Pold M, Mao JT. Cyclooxygenase-2 in lung cancer. Prog Exp Tumor Res 2003;37:138-62.
13. Gridelli C, Maione P, Airoma G, Rossi A. Selective cyclooxygenase-2 inhibitors and non-small cell lung cancer. Curr Med Chem 2002;9:1851-8.
14. Ermert L, Dierkes C, Ermert M. Immunohistochemical expression of cyclooxygenase isoenzymes and downstream enzymes in human lung tumors. Clin Cancer Res 2003;9:1604-10.
15. Dubois RN. Review article: cyclooxygenase-a target for colon cancer prevention. Aliment Pharmacol Ther 2000;141 Suppl 1:64-7.
16. Foy JW, Silverman DM, Schatz RA. Low-level m-xylene inhalation alters pulmonary and hepatic cytochrome P-450 activity in the rat. J Toxicol Environ Health 1996;47:135-44.
17. Lanningham-Foster L, Green CL, Langkamp-Henken B, et al. Overexpression of CRIP in transgenic mice alters cytokine patterns and the immune response. Am J Physiol Endocrinol Metab 2002;282:E1197-203.
18. Cousins RJ, Lanningham-Foster L. Regulation of cysteine-rich intestinal protein, a zinc finger protein, by mediators of the immune response. J Infect Dis 2000;182 Suppl 1:S81-4.
19. Rodrigues S, Nguyen QD, Faivre S, et al. Activation of cellular invasion by trefoil peptides and src is mediated by cyclooxygenase- and thromboxane A2 receptor-dependent signaling pathways. FASEB J 2001;15:1517-28.
20. Tarnawski A, Szabo IL, Husain SS, Soreghan B. Regeneration of gastric mucosa during ulcer healing is triggered by growth factors and signal transduction pathways. J Physiol (Paris) 2001;95:337-44.
21. Rodrigues S, Van Aken E, Van Bocxlaer S, et al. Trefoil peptides as proangiogenic factors in vivo and in vitro: implication of cyclooxygenase-2 and EGF receptor signaling. FASEB J 2003;17:7-16.
22. Welter C, Theisinger B, Seitz G, et al. Association of the human spasmolytic polypeptide and an estrogen-induced breast cancer protein (pS2) with human pancreatic carcinoma. Lab Invest 1992;66:187-92.
23. Yeh TS, Jan YY, Chiu CT, et al. Characterization of estrogen receptor, progesterone receptor, trefoil factor 1, and epidermal growth factor and its receptor in pancreatic cystic neoplasms and pancreatic ductal adenocarcinoma. Gut 2002;51:712-6.
24. Leung WK, Yu J, Chan FK, et al. Expression of trefoil peptides (TFF1, TFF2, and TFF3) in gastric carcinomas, intestinal metaplasia, and non-neoplastic gastric tissues. J Pathol 2002;197:582-8.
25. Tan XD, Chen YH, Liu QP, Gonzalez-Crussi F, Liu XL. Prostanoids mediate the protective effect of trefoil factor 3 in oxidant-induced intestinal epithelial cell injury: role of cyclooxygenase-2. J Cell Sci 2000;113 Pt 12:2149-55.
26. Faure J, Dagher MC. Interactions between Rho GTPases and Rho GDP dissociation inhibitor (Rho-GDI). Biochimie 2001;83:409-14.
27. Moscow JA, Gong M, He R, et al. Isolation of a gene encoding a human reduced folate carrier (RFC1) and analysis of its expression in transport-deficient, methotrexate-resistant human breast cancer cells. Cancer Res 1995;55:3790-4.
28. +- dependent 15-hydroxyprostaglandin dehydrogenase is involved in the interaction with prostaglandin substrates. Eur J Biochem 2001;268:3368-74.
29. Paulsen F, Hinz M, Schaudig U, Thale A, Hoffmann W. TFF peptides in the human efferent tear ducts. Invest Ophthalmol Vis Sci 2002;43:3359-64.
30. Imaoka S, Hiroi T, Tamura Y, et al. Mutagenic activation of 3-methoxy-4-aminoazobenzene by mouse renal cytochrome P450 CYP4B1: cloning and characterization of mouse CYP4B1. Arch Biochem Biophys 1995;321:255-62.